Engineered Acid Alpha-Glucosidase for Pompe Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Pompe disease, particularly enzyme replacement therapy, do not adequately address the severe forms of the condition, such as infantile Pompe disease, which is rapidly progressive and often fatal due to cardiorespiratory insufficiency, highlighting the need for improved therapeutic options.
Innovation Solution
Engineered acid alpha-glucosidase polypeptides with enhanced catalytic activity, stability, and reduced immunogenicity are developed, offering improved properties over naturally occurring enzymes, including increased expression and stability in lysosomes, and enhanced cellular uptake.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy using recombinant human acid alpha-glucosidase is used, then treatment is provided for Pompe disease, but the treatment does not adequately address severe forms such as infantile Pompe disease
Solution Approach 1:
The patent applies parameter changes by modifying the enzyme's molecular properties through site-directed mutagenesis. Specific amino acid residues were mutated to alter the enzyme's catalytic activity, stability, and interaction with cellular components. This resulted in engineered GAA variants with enhanced enzymatic activity and improved pharmacokinetic properties, directly addressing the insufficiency of wild-type enzyme therapy in severe forms of Pompe disease.
Solution Approach 2:
The engineered acid alpha-glucosidase variants represent composite materials in the sense that they combine multiple functional improvements within a single protein molecule. The enzyme incorporates enhanced catalytic domains, improved stability elements, and optimized binding sites, creating a multifunctional therapeutic agent that simultaneously addresses catalytic insufficiency and stability issues in severe Pompe disease patients.
2Productivity
If naturally occurring acid alpha-glucosidase is used, then enzyme replacement is provided, but catalytic activity and stability are insufficient for severe disease forms
Solution Approach 1:
The patent applies local quality by making specific targeted modifications to particular regions of the enzyme molecule. Site-directed mutagenesis was used to alter specific amino acid residues at defined positions in the protein sequence, optimizing local catalytic sites and stability domains while maintaining the overall enzyme structure. This localized optimization resulted in enhanced catalytic activity and improved stability without compromising the enzyme's fundamental function.
3Ease of operation
If wild-type acid alpha-glucosidase is administered, then treatment is provided, but immunogenicity and cellular uptake are insufficient
Solution Approach 1:
The patent modifies the enzyme's physical and chemical parameters through protein engineering. Specific amino acid sequences were altered to change the enzyme's surface properties, glycosylation patterns, and interaction interfaces with cellular components. These parameter changes resulted in engineered variants with enhanced cellular uptake mechanisms and reduced immunogenicity, allowing the enzyme to be more effectively absorbed and processed by target cells while minimizing immune reactions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered acid alpha-glucosidase polypeptides demonstrate improved enzymatic activity and stability, potentially leading to more effective treatment and management of Pompe disease, including the severe infantile form, by enhancing glycogen breakdown and reducing cellular damage.
Implementation Method 1
acid alpha-glucosidase (GAA)... enhanced catalytic activity... enhancing glycogen breakdown
Data Source
AI summary
The present disclosure provides engineered acid alpha-glucosidase polypeptides, recombinant polynucleotides encoding the engineered acid alpha-glucosidase polypeptides, and method of using the engineered acid alpha-glucosidase polypeptides and the recombinant polynucleotides for therapeutic purposes.